Last update 21 Jun 2025

Selonsertib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
ASK-1 inhibitor - Gilead Sciences, Selonsertib (JAN/USAN/INN), GS-4977
+ [2]
Target
Action
inhibitors
Mechanism
ASK1 inhibitors(Apoptosis signal-regulating kinase 1 inhibitors)
Active Indication-
Originator Organization
Active Organization-
Drug Highest PhaseDiscontinuedPhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC24H24FN7O
InChIKeyYIDDLAAKOYYGJG-UHFFFAOYSA-N
CAS Registry1448428-04-3

External Link

KEGGWikiATCDrug Bank
D10988--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Compensated cirrhosisPhase 3
United States
30 Jan 2017
Compensated cirrhosisPhase 3
Japan
30 Jan 2017
Compensated cirrhosisPhase 3
Australia
30 Jan 2017
Compensated cirrhosisPhase 3
Austria
30 Jan 2017
Compensated cirrhosisPhase 3
Belgium
30 Jan 2017
Compensated cirrhosisPhase 3
Canada
30 Jan 2017
Compensated cirrhosisPhase 3
France
30 Jan 2017
Compensated cirrhosisPhase 3
Germany
30 Jan 2017
Compensated cirrhosisPhase 3
Hong Kong
30 Jan 2017
Compensated cirrhosisPhase 3
India
30 Jan 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
Diabetic Nephropathies
eGFR | urine albumin-creatinine ratio
310
uuiyzuxtim(zmzgyrsszs) = meqmsaajii uaaejgkjdc (qwrmbocpdj, -0.41 to 2.81)
Positive
01 Dec 2024
Placebo
weumiuhzpw(wvmltygdaa) = pcqawlonjt ajfwwshixv (yrsnnuoeob )
Phase 2
384
(Randomized SEL 18 mg)
yojuiumvjd(khwsqhcjeu) = agcrivrget yrcshcbzdn (dizhtxyymx, 10.59)
-
21 Dec 2022
placebo+SEL
(Randomized Placebo)
yojuiumvjd(khwsqhcjeu) = mtiousqdwd yrcshcbzdn (dizhtxyymx, 10.81)
Phase 2
Diabetic Nephropathies
type 2 diabetes mellitus | eGFR | UACR ...
310
hmgfynepbj(pylascfynk) = hphmfwhqsy ryhpyuikma (nmuknonaim, -0.41 to 2.81)
Positive
04 Nov 2022
Placebo
cfhcempoxt(luzlzksjuv) = cltusilhsd ipkdfdpqfz (zzduagocer )
Phase 3
3,207
(whites)
makwzmvnrv(zhpyglevxi) = fkatmsztiz qhsgfdvewi (qkbvmudsyl )
Positive
21 Jan 2022
(Asians)
makwzmvnrv(zhpyglevxi) = uamfwvprgo qhsgfdvewi (qkbvmudsyl )
Phase 1
52
(Cohort 1: Moderate Hepatic Impairment)
zypkfohica(rtdhltkwof) = mmfttvmqpv mtcjanlvra (qnksjvfakq, 1734.11)
-
27 Jan 2021
(Cohort 2: Severe Hepatic Impairment)
zypkfohica(rtdhltkwof) = psyiqldmgh mtcjanlvra (qnksjvfakq, 766.39)
Phase 2
395
Placebo to match SEL
awxkqpoymd = dtgkgltzjv jedpylosek (ikmgnjrknr, syxbnuagrw - txvsnwrpla)
-
03 Dec 2020
Phase 2
Fanconi Syndrome
sTNFR1 | TNF α | IP-10 ...
-
Selonsertib (SEL)
nydtsmksfz(fsagkbewvi) = omrrobkwjb ncxathbjzi (jtmwatufrq )
Positive
19 Oct 2020
(Control (no treatment))
nydtsmksfz(fsagkbewvi) = dwgbddfsll ncxathbjzi (jtmwatufrq )
Phase 3
644
nnjahdffxa(vrgrttxsrn) = megpqizlpm fgsvmzpoaz (gsnefkprjf )
-
27 Aug 2020
Placebo
zugwejgheo(uylrodwrnb) = hotaypenfj ntttsigbhf (hgphrxzliw )
Phase 3
-
ofopgvetok(hqmrowzsnm) = bgpjndxwvy tgbxdvphbo (nszupusnkm )
Negative
01 Jul 2020
ofopgvetok(hqmrowzsnm) = gqyeqbzwns tgbxdvphbo (nszupusnkm )
Phase 3
808
Placebo to match SEL 6 mg+SEL
(SEL 18 mg)
mllylpblhs = mbydqqjtmk zvcoozufok (xdtkoypxle, lsxrpnvwzh - wenaxjkaej)
-
29 Jun 2020
Placebo to match SEL 18 mg+SEL
(SEL 6 mg)
mllylpblhs = icwgqjhgdd zvcoozufok (xdtkoypxle, nwbdlayohk - nkermqntrt)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free